This disparity in pathway enrichment between upregulated and downregulated genes underscores the specific impact of metabolic-immune alterations on the upregulated gene expression profile in MDS, pointing to a gene expression program driven by PSAT1. Here, PSAT1 is linked to myelodysplastic syndrome.